Clinical Trials Directory

Trials / Unknown

UnknownNCT02344784

The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder

The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.

Status
Unknown
Phase
Study type
Observational
Enrollment
46 (actual)
Sponsor
HaEmek Medical Center, Israel · Academic / Other
Sex
All
Age
7 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to show that Prepulse inhibition test of acoustic startle response is an indicator of objective diagnostic characteristics of attention deficit disorder in children and adolescents. by demonstrating that Prepulse inhibition test of acoustic startle response is impaired in children and adolescents suffering from attention deficit disorder in the relation to the normal function described in the literature. The investigators will try to prove our hypothesis by an experiment that consists of two phases: Phase I (about 25 minutes): The patient will enter the room, will be asked to sit on a chair, and will be asked to look at a computer screen showing silent video of aquarium fish, then the patient will be connected to both the Prepulse inhibition test device and the Galvanic skin response device and pass the tests. Phase II (about 25 minutes): After completion of Phase I, each participant will receive his daily regular dose of methylphenidate and after an hour and a half from taking the drug, will repeat the tests, both the Prepulse inhibition test and the Galvanic skin response test. Duration of the entire experiment is 140 minutes (two hours and twenty minutes).

Conditions

Interventions

TypeNameDescription
DEVICESR-HLAB EMGPrepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
DRUGMethylphenidateThe regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test

Timeline

Start date
2015-01-01
Primary completion
2017-03-01
Completion
2017-06-01
First posted
2015-01-26
Last updated
2016-08-23

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT02344784. Inclusion in this directory is not an endorsement.